Cover Image

The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration

Anti-vascular endothelial growth factor drugs keep being the main therapy for neovascular age-related macular degeneration (AMD). Possible predictive parameters (demographic, biochemical and/or inflammatory) could anticipate short-term treatment response with ranibizumab. 46 treatment-naive patients...

Full description

Saved in:

Bibliographic Details
Main Authors:	Laura García-Quintanilla (Author), Pablo Almuiña-Varela (Author), María José Rodríguez-Cid (Author), María Gil-Martínez (Author), Maximino J. Abraldes (Author), Francisco Gómez-Ulla (Author), Miguel González-Barcia (Author), Cristina Mondelo-García (Author), Ana Estany-Gestal (Author), Francisco J. Otero-Espinar (Author), Maribel Fernández-Rodríguez (Author), Anxo Fernández-Ferreiro (Author)
Format:	Book
Published:	MDPI AG, 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab
by: Pablo Almuiña-Varela, et al.
Published: (2024)

Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization
by: Petrou P, et al.
Published: (2013)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021)

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Jose Navarro-Partida, et al.
Published: (2021)

Severe hypotony and filtering bleb leak after intravitreal injection of ranibizumab
by: Ilias Georgalas, et al.
Published: (2008)

Use of ranibizumab for the treatment of subretinal neovascularization in pathologic myopia: a prospective study
by: О.M. Blavatska, et al.
Published: (2016)

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials
by: Wei Q, et al.
Published: (2019)

Intravitreal long-term sustained ranibizumab delivery using injectable microgel-embedded hydrogel
by: Simin Lee, et al.
Published: (2024)

Evaluation of intravitreal ranibizumab injection as a line of treatment for chronic central serous retinopathy
by: Emad A.A Saliem
Published: (2019)

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
by: Wang LP, et al.
Published: (2018)

Ocular Biodistribution Studies using Molecular Imaging
by: Ana Castro-Balado, et al.
Published: (2019)

Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation
by: Yan PS, et al.
Published: (2016)

Genetic Polymorphisms in VEGFR Coding Genes (<i>FLT1</i>/<i>KDR</i>) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients
by: David Blánquez-Martínez, et al.
Published: (2022)

Occult retinal neovascularization following intravitreal bevacizumab and laser treatment for retinopathy of prematurity
by: Wei Loon Ng, et al.
Published: (2024)

Effects of intravitreal injection of netrin-1 in retinal neovascularization of streptozotocin-induced diabetic rats
by: Yu Y, et al.
Published: (2015)

Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors
by: Fabiana Mallone, et al.
Published: (2021)

Analysis of intravitreal using of anti vegf-medications for diseases of fundus accompanied by exudation and neovascularization
by: N. G. Zavgorodnya, et al.
Published: (2013)

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report
by: Gianluca Trifirò, et al.
Published: (2018)

Sterile Endophthalmitis after Intravitreal Injections
by: Joaquín Marticorena, et al.
Published: (2012)

Vascular endothelial growth factor-A level in human breast milk after intravitreal injection of ranibizumab: a case report
by: Ying Huang, et al.
Published: (2022)

Erratum to "Sterile Endophthalmitis after Intravitreal Injections"
by: Joaquín Marticorena, et al.
Published: (2013)

Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model
by: Xurxo García-Otero, et al.
Published: (2021)

First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration
by: Wissam Aljundi, et al.
Published: (2024)

Erratum found in «Farmacia Hospitalaria. 2020;44(4):149-57»
by: Ana Castro-Balado, et al.
Published: (2021)

Development and Characterization of a Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drop
by: Xurxo García-Otero, et al.
Published: (2021)

Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review
by: Manuel Busto-Iglesias, et al.
Published: (2023)

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy
by: Peng Y, et al.
Published: (2018)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022)

Ranibizumab Port Delivery System in Neovascular Age-Related Macular Degeneration: Where Do We Stand? Overview of Pharmacokinetics, Clinical Results, and Future Directions
by: Matteo Mario Carlà, et al.
Published: (2024)

Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence
by: Ana Castro-Balado, et al.
Published: (2022)

Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration
by: Joanna Dolar-Szczasny, et al.
Published: (2021)

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA
by: Francisco José Toja-Camba, et al.
Published: (2023)

Treatment of syndrome of inappropriate antidiuretic hormone secretion due to sertraline
by: Pedro Suárez Artime, et al.
Published: (2015)

Efficacy and Safety of Inhaled Ethanol in Early-Stage SARS-CoV-2 Infection in Older Adults: A Phase II Randomized Clinical Trial
by: Ana Castro-Balado, et al.
Published: (2023)

Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis
by: Andrea Luaces-Rodríguez, et al.
Published: (2018)

Clinical outcomes of a treat-and-extend regimen with intravitreal aflibercept injections in patients with choroidal neovascularization secondary to chronic central serous chorioretinopathy
by: T. B. Kustryn, et al.
Published: (2024)

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations
by: Rubén Varela-Fernández, et al.
Published: (2020)

Recent Research in Ocular Cystinosis: Drug Delivery Systems, Cysteamine Detection Methods and Future Perspectives
by: Ana Castro-Balado, et al.
Published: (2020)

Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
by: David Blánquez-Martínez, et al.
Published: (2021)